Virtual Plenary Sessions

CT031 - COM701 demonstrates preliminary antitumor activity as monotherapy and in combination with nivolumab in patients with advanced solid tumors
Ryan Sullivan, Drew Rasco, Emerson Lim, Manish Sharma, Dale Shepard, Amita Patnaik, Erika Hamilton, Gini Fleming, Kyri Papadopoulos, Adam ElNaggar, Adeboye Henry Adewoye, Bartosz Chmielewski, Ecaterina Dumbrava, Dan Vaena. Massachusetts General Hospital, Harvard Medical School, Boston, MA, South Texas Accelerated Research Therapeutics, San Antonio, TX, Columbia University-Herbert Irving Comprehensive Cancer Center, New York City, NY, START Midwest, Grand Rapids, MI, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Tennessee Oncology, PLLC and Sarah Cannon Research Institute, Nashville, TN, University of Chicago School of Medicine., Chicago, IL, University of Tennessee West Cancer Center, Memphis, TN, Compugen USA, Inc., South San Francisco, CA, David Geffen School of Medicine at UCLA, Los Angeles, CA, The University of Texas MD Anderson Cancer Center, Houston, TX
11:45 AM - 11:55 AM
April 27, 2020, 11:40 AM - 2:00 PM; VCTPLO3 - Immunotherapy Clinical Trials 1
https://www.abstractsonline.com/pp8/#!/9045/session/852
https://www.abstractsonline.com/pp8/#!/9045/presentation/10741
Session Type: Virtual Plenary Session
Track(s): Clinical Trials, Immunology

CT032 - A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies
Antonio Jimeno, Shilpa Gupta, Ryan Sullivan, Khanh T. Do, Wallace L. Akerley, Ding Wang, Deanna Teoh, Kurt Schalper, Sima J. Zacharek, Jing Sun, Andressa S. Laino, Joshua Frederick, Honghong Zhou, William Randolph, Stephanie Pascarella, Lisa Johansen, Pamela S. Cohen, ROBERT S. MEEHAN Sr., Todd M. Bauer. University of Colorado Cancer Center, Aurora, CO, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, OH, Massachusetts General Hospital, Boston, MA, Dana Farber Cancer Institute, Boston, MA, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, Henry Ford Hospital, Detroit, MI, University of Minnesota Medical Center, Minneapolis, MN, Yale School of Medicine, New Haven, CT, MODERNA Tx INC., CAMBRIDGE, MA, Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, TN
12:00 PM - 12:10 PM
April 27, 2020, 11:40 AM - 2:00 PM; VCTPLO3 - Immunotherapy Clinical Trials 1
https://www.abstractsonline.com/pp8/#!/9045/session/852
https://www.abstractsonline.com/pp8/#!/9045/presentation/10742
Session Type: Virtual Plenary Session
Track(s): Clinical Trials, Immunology
CT021 - Prediction of cancer and tissue of origin in individuals with suspicion of cancer using a cell-free DNA multi-cancer early detection test
1:25 PM - 1:35 PM
April 28, 2020, 1:20 PM - 3:20 PM; VCTPL02 - Early Detection and ctDNA
https://www.abstractsonline.com/pp8/#I/9045/presentation/10733
https://www.abstractsonline.com/pp8/#I/9045/session/848
Session Type: Virtual Plenary Session
Track(s): Clinical Trials

Virtual Minisymposia

3403 - Drugging the undruggable: Lessons learned from protein phosphatase 2A
Derek Taylor, Goutham Narla. Case Western Reserve University, Cleveland, OH, University of Michigan, Ann Arbor, MI
2:50 PM - 3:00 PM
April 27, 2020, 1:30 PM - 3:30 PM; VMS.ET01.01 - Drugging Undrugged Cancer Targets
https://www.abstractsonline.com/pp8/#I/9045/session/835
https://www.abstractsonline.com/pp8/#I/9045/presentation/10545
Session Type: Virtual Minisymposium
Track(s): Experimental and Molecular Therapeutics, Drug Development

5705 - Mechanisms and therapeutic implications of hypermutation in gliomas
Mehdi Touat, Yvonne Y. Li, Adam N. Boynton, Liam F. Spurr, Bryan Iorgulescu, Craig L. Bohrson, Isidro Cortes-Ciriano, Jack E. Geduldig, Kristine Pelton, Mary J. Lim-Fat, Sangita Pal, Shakti H. Ramkissoon, Frank Dubois, Charlotte Bellamy, Naomi Currimjee, Kenin Qian, Seth Malinowski, Aniket Shetty, Kin-Hoe Chow, Maité Verreault, Erell Guillerm, Samy Ammari, Frédéric Beuvon, Karima Mokhtari, Agusti Alentorn, Caroline Dehais, Caroline Houillier, Florence Laigle-Donaday, Dimitri Psimaras, Alexandre Carpentier, Philippe Cornu, Laurent Capelle, Bertrand Mathon, Jill S. Barnholtz-Sloan, Arnab Chakravarti, Wenya L. Bi, Garrett M. Frampton, Marc Sanson, Brian M. Alexander, Andrew Cherniack, Patrick Y. Wen, David A. Reardon, Aurelien Marabelle, Peter J. Park, Ahmed Idbaih, Rameen Beroukhim, Pratiti Bandopadhayay, Franck Bielle, Keith L. Ligon. Dana-Farber Cancer Institute, Boston, MA, Dana-Farber Cancer Institute, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, MA, Dana-Farber Cancer Institute, Boston, MA, Harvard Medical School, Boston, MA, European Molecular European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United Kingdom, Broad Institute of MIT and Harvard, Cambridge, MA, Foundation Medicine Inc, Cambridge, MA, Dana-Farber Cancer Institute, Boston, MA, Sorbonne Université, Inserm, Paris, France, France, Hôpitaux Universitaires La Pitié Salpêtrière, Paris, France, Gustave Roussy, Villejuif, France, Université Paris Descartes, Hôpital Cochin, Paris, France, Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière, Paris, France, Case Western Reserve University School of Medicine, Cleveland, OH, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Cleveland, OH, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, Foundation Medicine, Boston, MA, Sorbonne Université, France, Dana Farber Cancer Institute, Boston, MA, Gustave Roussy, Paris, France, Harvard Medical School, Boston, MA, Sorbonne Université, France, Sorbonne Université, Paris, France
Virtual Poster Sessions

CT134 - Tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling in solid tumors
Hani M. Babiker, Vivek Subbiah, Asim Ali, Alain Algazi, Jacob Schachter, Michal Lotem, Corinne Maurice-Dror, Daniel Hendler, Shah Rahimian, Hans Minderman, Cara Haymaker, Chantale Bernatchez, Ravi Murthy, Rolf Hultsch, Nadia Caplan, Gregory Woodhead, Charles Hennemeyer, Sri Chunduru, Peter Anderson, Adi Diab, Erkut Borazanci, Igor Puzanov. University of Arizona Cancer Center, Tucson, AZ, University of Texas MD Anderson Cancer Center, Houston, TX, Saint Luke’s University Health Network, Easton, PA, University of California, San Francisco, CA, Sheba Medical Center, Tel HaShomer, Israel, Hadassah Hebrew University Medical Center, Jerusalem, Israel, Rambam Health, Haifa, Israel, Rabin Medical Center, Petach Tikva, Israel, Idera Pharmaceuticals, Exton, PA, Roswell Park Comprehensive Cancer Center, Buffalo, NY, HonorHealth, Scottsdale, AZ, Cleveland Clinic, Cleveland, OH
9:00 AM - 6:00 PM
April 27, 2020, 9:00 AM - 6:00 PM; VPO.CT01 - Phase I Clinical Trials
https://www.abstractsonline.com/pp8/#/9045/session/842
Session Type: Virtual Poster Session
Track(s): Clinical Trials

CT236 - A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposis
Eduardo Vilar-Sanchez, Carol Burke, Marcia R. Cruz Correa, Evelien Dekker, William M. Grady, Philippe Grandval, Bryson W. Katona, Xavier Llor, Douglas L. Riegert-Johnson, Jean-Christophe Saurin, Peter Stanich, Daniel A. Sussman, David Weinberg, Edward F. Attiyeh, Devanand Joseph, Kelly Raybold, Gary V. Borzillo, Thomas J. Prior, Michael Smith, Hong Xie, Kurtis E. Bachman, Jeffrey R. Infante, Niloy Jewel Samadder. MD Anderson Cancer Center, Houston, TX, Cleveland Clinic, Cleveland, OH, University of Puerto Rico School of Medicine, San Juan, PR, Amsterdam University Medical Centers, Amsterdam, Netherlands, Fred Hutchinson Cancer Research Center and University of Washington, School of Medicine, Seattle, WA, Assistance Publique Hôpitaux de Marseille, Marseille, France, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, Department of Medicine and Cancer Center, Yale University, New Haven, CT, Mayo Clinic, Jacksonville, FL, Hôpital Edouard Herriot, Lyon, France, Ohio State University Wexner Medical Center, Columbus, OH, University of Miami Miller School of Medicine, Miami, FL, Fox Chase Cancer Center, Philadelphia, PA, Janssen Research & Development, LLC, Spring House, PA, Mayo Clinic, Phoenix, AZ
9:00 AM - 6:00 PM
April 27, 2020, 9:00 AM - 6:00 PM; VPO.CT07.01 - Phase I Trials in Progress
https://www.abstractsonline.com/pp8/#/9045/presentation/10664
https://www.abstractsonline.com/pp8/#/9045/session/845
Session Type: Virtual Poster Session
Track(s): Clinical Trials
CT281 - Pivotal study of the LUM Imaging System for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancer
Jorge Ferrer, David Carr, Irene Wapnir, Kelly Hunt, Peter Blumencranz, Nayana Dekhne, Daleela Dodge, Donna Lynn Dyess, Shelley Hwang, Stephanie Valente, Lynne Clark, Beth-Ann Lesnikoski, Anees Chagpar, Paticia Clark, Marie Catherine Lee, Brian Schlossberg, Sean Madden, Livia Gjylameti, Manna Chang, Kate Smith, Barbara Smith. Lумicell, Inc, Newton, MA, Novant Health, Winston-Salem, NC, Stanford Cancer Institute, Stanford, CA, The University of Texas M.D. Anderson Cancer Center, Houston, TX, The Comprehensive Breast Care Center of Tampa Bay (BayCare), Clearwater, FL, Beaumont Health System, Royal Oak, MI, Penn State Milton S. Hershey Medical Center, Hershey, PA, Mitchell Cancer Institute-University of South Alabama, Mobile, AL, Duke University Medical Center, Durham, NC, Cleveland Clinic Foundation, Cleveland, OH, CHI Franciscan Research Center, Tacoma, WA, Baptist MD Anderson Cancer Center, Jacksonville, FL, Yale University-Smilow Cancer Center, New Haven, CT, HonorHealth Research Institute, Scottsdale, AZ, Moffitt Cancer Center, Tampa, FL, Massachusetts General Hospital, Boston, MA
9:00 AM - 6:00 PM
April 27, 2020, 9:00 AM - 6:00 PM; VPO.CT07.03 - Phase III Trials in Progress
https://www.abstractsonline.com/pp8/#!/9045/session/847
https://www.abstractsonline.com/pp8/#!/9045/presentation/10721
Session Type: Virtual Poster Session
Track(s): Clinical Trials

CT291 - The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice
9:00 AM - 6:00 PM
April 27, 2020, 9:00 AM - 6:00 PM; VPO.CT07.03 - Phase III Trials in Progress
https://www.abstractsonline.com/pp8/#!/9045/session/847
https://www.abstractsonline.com/pp8/#!/9045/presentation/10731
Session Type: Virtual Poster Session
Track(s): Clinical Trials